Multi-Omics Reveals the Effects of Cannabidiol on Gut Microbiota and Metabolic Phenotypes.
Mengxue HeAiyang LiuJiachen ShiYong-Jiang XuYuanfa LiuPublished in: Cannabis and cannabinoid research (2023)
Introduction: Cannabidiol (CBD) has important pharmacological activity, which includes antispasmodic, antioxidant, antithrombotic, and antianxiety properties. CBD has been applied as a health supplement to atherosclerosis. However, CBDs effect on gut microbiota and metabolic phenotype is unclear. Materials and Methods: We constructed a high production of cardiovascular risk factors, such as trimethylamine-N-oxide (TMAO) and phenylacetylglutamine (PAGln), in a mouse model using Clostridium sporogenes colonization. We used 16S ribosomal RNA (rRNA) gene sequencing and ultra-high performance liquid chromatography-quadrupole time-of flight mass spectrometry-based metabolomics to evaluate the effect of CBD on gut microbiota and plasma metabolites. Results: CBD decreased the levels of creatine kinase (CK), alanine transaminase (ALT), and low-density lipoprotein cholesterol and markedly increased high-density lipoprotein cholesterol. Furthermore, CBD treatment increased the abundance of beneficial bacteria, which include Lachnospiraceae_NK4A136 and Blautia in the gut, but it decreased the levels of TMAO and PAGln in the plasma. Conclusion: CBD might have beneficial effects for cardiovascular protection.
Keyphrases
- cardiovascular risk factors
- tandem mass spectrometry
- mouse model
- ultra high performance liquid chromatography
- mass spectrometry
- cardiovascular disease
- simultaneous determination
- single cell
- metabolic syndrome
- ms ms
- public health
- mental health
- copy number
- protein kinase
- genome wide
- risk assessment
- tyrosine kinase
- high performance liquid chromatography
- social media
- human health
- replacement therapy
- anti inflammatory